Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback